Wed, October 20, 2010
Tue, October 19, 2010
Mon, October 18, 2010
Sun, October 17, 2010
Sat, October 16, 2010
Fri, October 15, 2010
[ Fri, Oct 15th 2010 ] - Market Wire
ALGN, FCN, GOOG, SWY, GCI
Thu, October 14, 2010
Wed, October 13, 2010
Tue, October 12, 2010
Mon, October 11, 2010
[ Mon, Oct 11th 2010 ] - Market Wire
SNY,GENZ,LH,AVB,MU
[ Mon, Oct 11th 2010 ] - Market Wire
ARAY,SI,VAR,TOMO,JMBA
Sun, October 10, 2010
Sat, October 9, 2010
Fri, October 8, 2010
Thu, October 7, 2010
[ Thu, Oct 07th 2010 ] - Market Wire
30pm CST
Wed, October 6, 2010
Tue, October 5, 2010
Mon, October 4, 2010
Sun, October 3, 2010
Fri, October 1, 2010
Thu, September 30, 2010
Wed, September 29, 2010
Tue, September 28, 2010

30 am ET October 11, 2010 to Discuss New Collaboration and Updated Guidance for Fiscal Year 2011


//health-fitness.news-articles.net/content/2010/ .. n-and-updated-guidance-for-fiscal-year-2011.html
Published in Health and Fitness on Monday, October 11th 2010 at 3:20 GMT by Market Wire   Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc. ] (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that it will host a conference call at 8:30 am ET on Monday, October 11, 2010 to discuss the Company's new collaboration announced this morning and its updated financial guidance for ImmunoGena™s fiscal year ending June 30, 2011.

To access the live call by phone, dial 913-312-0658. Passcode is 4078495. The call also may be accessed through the Investor Information section of the Company's website, [ www.immunogen.com ]. Following the live webcast, a replay of the call will be available at the same location through October 18, 2010.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Companya™s expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Companya™s TAP technology uses monoclonal antibodies to deliver one of ImmunoGena™s proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGena™s TAP technology, T-DM1, is in Phase III testing through the Companya™s collaboration with Genentech. More information about ImmunoGen can be found at [ www.immunogen.com ].


Publication Contributing Sources